Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Moodys
McKesson
Johnson and Johnson
Express Scripts

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AKB-6548

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AKB-6548?

AKB-6548 is an investigational drug.

There have been 31 clinical trials for AKB-6548. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Aerpio Therapeutics, and Mitsubishi Tanabe Pharma Corporation.

There are thirteen US patents protecting this investigational drug and one hundred and seven international patents.

Recent Clinical Trials for AKB-6548
TitleSponsorPhase
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney DiseaseAkebia TherapeuticsPhase 1
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin AlfaAkebia TherapeuticsPhase 2
Effects of Iron Supplements on the Pharmacokinetics of MT-6548Mitsubishi Tanabe Pharma CorporationPhase 3

See all AKB-6548 clinical trials

Clinical Trial Summary for AKB-6548

Top disease conditions for AKB-6548
Top clinical trial sponsors for AKB-6548

See all AKB-6548 clinical trials

US Patents for AKB-6548

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AKB-6548   Start Trial Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
AKB-6548   Start Trial Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
AKB-6548   Start Trial Prolyl hydroxylase inhibitors and methods of use Warner Chilcott Company, LLC (Pajardo, PR)   Start Trial
AKB-6548   Start Trial Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics Inc. (Cincinnati, OH)   Start Trial
AKB-6548   Start Trial Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics Inc. (Cincinnati, OH)   Start Trial
AKB-6548   Start Trial Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics, Inc. (Cincinnati, OH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AKB-6548

Drugname Country Document Number Estimated Expiration Related US Patent
AKB-6548 Argentina 099354 2033-11-15   Start Trial
AKB-6548 Australia 2014348523 2033-11-15   Start Trial
AKB-6548 Australia 2019202144 2033-11-15   Start Trial
AKB-6548 Canada 2930128 2033-11-15   Start Trial
AKB-6548 Chile 2016001150 2033-11-15   Start Trial
AKB-6548 China 105916502 2033-11-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Dow
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.